Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; purified talc; disodium edetate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - endep 50mg tablets are indicated only for the maintenance treatment of major depression. (see precautions). nocturnal enuresis where organic pathology has been excluded.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxepin hydrochloride, quantity: 28.25 mg (equivalent: doxepin, qty 25 mg) - capsule, hard - excipient ingredients: purified talc; sodium starch glycollate; titanium dioxide; gelatin; lactose monohydrate; colloidal anhydrous silica; brilliant blue fcf; erythrosine; sodium lauryl sulfate; magnesium stearate - for the treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxepin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - hyoscine butylbromide, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - spasm of the gastrointestinal tract, biliary spasm, renal spasm, diagnostic aid in radiology.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - glibenclamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: sorbitol; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; saccharin sodium; brilliant scarlet 4r; purified water; sucrose; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - ointment - excipient ingredients: white soft paraffin - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.